Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496353
Status:
COMPLETED
Last Update Posted:
2015-03-31
First Post:
2007-07-02
Brief Title:
MK2461 Phase III Study in Patients With Advanced Solid Tumors MK-2461-002 AM1COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase III Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this phase I portion are 1 to evaluate the safety and tolerability of MK2461 and 2 to determine the recommended phase 2 dose or doses of MK2461
The purpose of the phase II portion is to evaluate the anti-tumor efficacy of MK2461
The purpose of the phase II portion is to evaluate the anti-tumor efficacy of MK2461
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_016 | None | None | None |